CAPASTAT SULFATE
CAPREOMYCIN SULFATE
Approval overview CAPASTAT SULFATE is listed in Drugs@FDA under application 050095 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CAPREOMYCIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EPIC PHARMA LLC Submission history Latest submission status date: 2023-01-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview CAPASTAT SULFATE is listed in Drugs@FDA under application 050095 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CAPREOMYCIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EPIC PHARMA LLC Submission history Latest submission status date: 2023-01-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.